Clinical Outcomes in Patients With Parkinson's Disease Treated With a Monoamine Oxidase Type-B Inhibitor: A Cross-Sectional, Cohort Study

Pharmacotherapy. 2015 Jul;35(7):681-6. doi: 10.1002/phar.1611. Epub 2015 Jul 3.

Abstract

Study objective: To evaluate the long-term risk of developing cognitive symptoms (e.g., dementia, hallucinations), dyskinesia, falls, and freezing of gait (FoG) in patients with Parkinson's disease (PD) who received monoamine oxidase type B inhibitors (MAOB-Is) compared with patients who had never received MAOB-Is.

Design: Retrospective, cross-sectional, cohort study.

Setting: Academic movement disorders clinic.

Patients: One hundred eighty-one patients with idiopathic PD who were receiving MAOB-I therapy on a long-term basis for a minimum of 1 year (MAOB-I current-user cohort) and 121 patients with idiopathic PD who had never received MAOB-I therapy (MAOB-I never-user cohort [control group]) between January 1, 1996, and November 30, 2011.

Measurements and main results: The five study outcome variables were dementia, dyskinesia, falls, FoG, and hallucinations. Baseline and outcome data were collected from medical records. Patients in the MAOB-I current-user group were included only if absence of the specified outcomes was documented at baseline. Adjusted multiple logistic regression analyses were performed to calculate the odds ratios (ORs) for MAOB-I use versus never use on clinical outcomes. MAOB-I treatment was associated with a 44.7% reduced risk of dyskinesia (adjusted OR 0.553, 95% confidence interval 0.314-0.976, p=0.041), with the greatest risk reduction observed after 2 years of treatment. No significant association was noted with MAOB-I use and development of dementia, falls, FoG, or hallucinations.

Conclusion: Long-term use of MAOB-I therapy was associated with reduced risk of dyskinesia in patients with PD.

Keywords: Parkinson's disease; dyskinesia; monoamine oxidase inhibitor; rasagiline; selegiline.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Cross-Sectional Studies
  • Dyskinesias / drug therapy
  • Female
  • Humans
  • Male
  • Middle Aged
  • Monoamine Oxidase Inhibitors / therapeutic use*
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / physiopathology
  • Retrospective Studies

Substances

  • Monoamine Oxidase Inhibitors